As of 2026-03-24, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 13.8x | 13.3x |
| Forward P/E multiples | 14.5x - 23.3x | 16.2x |
| Fair Price | (55.46) - (52.52) | (56.34) |
| Upside | -131.0% - -129.4% | -131.5% |
| Date | EV/EBITDA |